Stocks Health care APGE
NASDAQ · Health careApogee Therapeutics, Inc. (APGE)
It posted a net loss of $294.4M. In fiscal 2025 capital spending exceeded operating cash flow by $232.6M. At June 30, 2026 it held $105.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Apogee Therapeutics, Inc.
- Net worth
- Apogee Therapeutics, Inc. has a market value (market cap) of $10.2B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Cash flow
- In fiscal 2025 operations used $227.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Apogee Therapeutics, Inc.'s next report is expected around December 25, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Apogee Therapeutics, Inc. does
Apogee Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker APGE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$255.8M | -$4.22 | -$232.6M |
| 2024 | n/a | -$182.1M | -$3.30 | -$172.3M |
| 2023 | n/a | -$84M | -$3.36 | -$74.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Apogee Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026Deregistration 15-12G
- September 8, 2026Activist stake changed SCHEDULE 13D/A
- September 3, 2026Activist stake changed SCHEDULE 13D/A
- September 3, 2026Form POSASR filing POSASR
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Form S-8 POS filing S-8 POS
- September 3, 2026Delisting notice 25-NSE
Insider trades
What the people running Apogee Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 11 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 3, 2026 | Fairmount Funds Management LLCDirector | Other changeindirect | 340,855 | - |
| September 3, 2026 | Fairmount Funds Management LLCDirector | Other changeindirect | 51,166 | - |
| September 3, 2026 | Fairmount Funds Management LLCDirector | Other changeindirect | 51,166 | - |
| September 3, 2026 | Shah Nimish PDirector | Other changeindirect | 1,750,000 | $236.4M |
| September 3, 2026 | Henderson Michael ThomasChief Executive Officer, Director | Other change | 920,941 | - |
| September 3, 2026 | Henderson JaneChief Financial Officer | Other change | 158,371 | - |
| September 3, 2026 | Fox Jennifer A.Director | Other change | 34,824 | - |
| September 3, 2026 | Dambkowski CarlChief Medical Officer | Other change | 167,123 | - |
Who owns APGE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fairmount Healthcare Fund II LP13D, may seek influence with 5 related filers | 9.99% | January 31, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 288 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Venrock Adviser, LLC | 8,493,321 | 0 |
| BlackRock, Inc. | 5,507,032 | +1,421,381 |
| Hbk Investments L P | 2,850,000 | new |
| Vanguard Capital Management LLC | 2,572,119 | +70,024 |
| Fmr LLC | 2,493,137 | -6,769,154 |
| State Street Corp | 2,297,743 | +134,779 |
| Driehaus Capital Management LLC | 1,740,101 | -180,699 |
| Goldman Sachs Group Inc | 1,693,341 | +1,040,751 |
| Balyasny Asset Management L.P. | 1,665,102 | +1,226,448 |
| Paradigm Biocapital Advisors LP | 1,576,385 | +228,142 |
| Vanguard Portfolio Management LLC | 1,528,750 | +1,132,420 |
| Millennium Management LLC | 1,491,404 | +1,398,812 |
| Pentwater Capital Management LP | 1,425,000 | new |
| Morgan Stanley | 1,421,681 | +826,649 |
| Geode Capital Management, LLC | 1,314,868 | +97,579 |
| Perceptive Advisors LLC | 1,308,113 | -232,271 |
| Jupiter Topco LLC | 1,193,626 | new |
| Bank of America Corp | 1,126,139 | +225,268 |
| Affinity Asset Advisors, LLC | 987,000 | -297,926 |
| Mercer Global Advisors Inc | 941,283 | +109,855 |
Insiders
Questions about APGE
What does Apogee Therapeutics, Inc. do?
Apogee Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as APGE. Its shares trade on NASDAQ under the ticker APGE.
What is Apogee Therapeutics, Inc.'s net worth?
Apogee Therapeutics, Inc. has a market value (market cap) of $10.2B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
Is Apogee Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $294.4M.
When did Apogee Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the deregistration from September 14, 2026.
When is Apogee Therapeutics, Inc.'s next earnings report?
Apogee Therapeutics, Inc.'s next report is expected around December 25, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare APGE with
Follow APGE
Get an email when Apogee Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Apogee Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.